The Patent Finder

Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment

Trisalus Life Sciences, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 15/064,158, filed Mar 8, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 12,377,245Method of Delivering a Therapeutic Agent to a Solid Tumor for Treatment
In force
 · High confidence
Trisalus Life Sciences, Inc.In force
High confidence
US 11,090,460Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment
In force
 · High confidence
Trisalus Life Sciences, Inc.In force
High confidence
US 12,433,597Atraumatic Occlusive System with Compartment for Measurement of Vascular Pressure Change
In force
 · High confidence
Trisalus Life Sciences, Inc.In force
High confidence
US 12,661,486Systems and Methods to Sense Characteristics of a Therapeutic Agent in Vivo
In force
 · Medium confidence
Trisalus Life Sciences, Inc.In force
Medium confidence
US 12,667,693Therapeutic Treatment Device with Braided Microvalve Occluder
In force
 · High confidence
Trisalus Life Sciences, Inc.In force
High confidence
US 8,372,413Immunomodulatory Polynucleotides and Methods of Using the Same
Term ended · USPTO later recorded non-payment Mar 17, 2025
Term ended Feb 2, 2023 · Medium confidence
Trisalus Life Sciences, Inc.Term ended
USPTO later recorded non-payment Mar 17, 2025
Term ended Feb 2, 2023
Medium confidence
US 8,158,768Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same
Term ended
Term ended Dec 18, 2023 · Medium confidence
Trisalus Life Sciences, Inc.Term endedTerm ended Dec 18, 2023
Medium confidence
US 8,871,732Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same
Term ended
Term ended Dec 18, 2023 · Medium confidence
Trisalus Life Sciences, Inc.Term endedTerm ended Dec 18, 2023
Medium confidence
US 9,422,564Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same
Term ended · USPTO later recorded non-payment Sep 30, 2024
Term ended Dec 18, 2023 · Medium confidence
Trisalus Life Sciences, Inc.Term ended
USPTO later recorded non-payment Sep 30, 2024
Term ended Dec 18, 2023
Medium confidence
US 10,196,643Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same
Term ended
Term ended Dec 18, 2023 · Medium confidence
Trisalus Life Sciences, Inc.Term endedTerm ended Dec 18, 2023
Medium confidence
10 more patents in this group · Pro
10 of 20 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 20, including 6 expired.
Upgrade to Pro
5 of these are in force and held by Trisalus Life Sciences, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited